Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Trastuzumab Deruxtecan in Metastatic Solid Tumors
NCT07015697Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in solid tumor (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Treatment Emergent Adverse Event at 9 months, Area Under Curve at 9 months and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07015697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015697.